Transcriptomics Market Forecasts to 2030 – Global Analysis By Component (Instruments, Services, Consumables, Software, Reagents and Other Components), Technology, Application, End User and By Geography

Transcriptomics Market Forecasts to 2030 – Global Analysis By Component (Instruments, Services, Consumables, Software, Reagents and Other Components), Technology, Application, End User and By Geography

According to Stratistics MRC, the Global Transcriptomics Market is accounted for $7.4 billion in 2023 and is expected to reach $13.5 billion by 2030 growing at a CAGR of 9.0% during the forecast period. The study of an organism's entire range of RNA transcripts is known as transcriptomics, and it offers valuable information about patterns of gene expression, regulatory systems, and cellular functions. In order to help researchers better understand how genes are activated or inhibited under various circumstances, the transcriptomics market includes tools and technologies that are intended to study and interpret an organism's whole transcriptome. Transcriptomics identifies disease-specific gene expression patterns and possible therapeutic targets in healthcare, enabling accurate diagnosis and individualized therapy strategies.

According to a research article titled ""High-Density Blood Transcriptomics Reveals Precision Immune Signatures of SARS-CoV-2 Infection in Hospitalized Individuals"" published in Frontiers in Immunology Journal in July 2021, the study had an average of 97.02% of sequences with perfect matching barcodes and a mean quality score of 35.59 ± 0.07, indicated that the sequencing was performed to a high level with low error.

Market Dynamics:

Driver:

Growing focus on personalized medicine

Because transcriptomics offers deep insights into each person's personal gene expression patterns, it is essential to this paradigm shift. Transcriptomic analysis, a key element of precision medicine, makes it possible to identify certain RNA molecules and gene signatures linked to diseases. With the use of this information, medical interventions can be specifically tailored to the molecular traits of each patient, resulting in more precise diagnoses, prognoses, and treatment strategies. Moreover, transcriptomics' capacity to identify small changes in gene expression aids in the creation of tailored treatments, reducing side effects, and increasing therapeutic effectiveness.

Restraint:

High initial costs

For research organizations and laboratories, acquiring cutting-edge equipment, specialty reagents, and computational resources comes at a substantial financial cost. Access to transcriptome technologies is restricted by this price barrier, especially for smaller research organizations with limited resources. The cost issue is made worse by the complex nature of the transcriptome analysis, which calls for sophisticated tools as well as skilled workers. However, the democratization of transcriptomics among the scientific community may be hampered for some researchers and institutions when attempting to include it in their research programs.

Opportunity:

Technological advancements

Improved accuracy, scalability, and affordability in transcriptomic analysis have resulted from ongoing advancements in high-throughput sequencing methods, such as RNA sequencing (RNA-Seq). Large-scale transcriptomic data sets can yield valuable insights that are further enhanced by the development of increasingly complex bioinformatics tools and computational techniques. Moreover, a more comprehensive understanding of biological processes is made possible by integration with other omics technologies, such as proteomics and genomics.

Threat:

Standardization and normalization issues

Reliability in comparing transcriptomic results is hampered by variability introduced by non-standardized processes for data analysis, reporting, and sample preparation. Inconsistencies originate from different experimental protocols and data processing methods, which reduce the validity of results and make it more difficult to establish generally recognized benchmarks. When combining data from several research projects or working with different universities, this problem is very apparent. Enhancing the reliability of transcriptome studies requires addressing standardization and normalization issues, requiring coordinated efforts to create standardized protocols, quality control procedures, and cooperative projects that establish best practices.

Covid-19 Impact:

Deciphering gene expression patterns, identifying possible treatment targets, and explaining immunological responses to the virus have all been made feasible, in large part due to transcriptomics. The pandemic has brought out difficulties, including supply chain interruptions that impede the availability of consumables and reagents necessary for transcriptomic studies. Transcriptomics study emphasis may also have been impacted by changes in funding and research priorities.

The next-generation sequencing (NGS) segment is expected to be the largest during the forecast period

Because Next-Generation Sequencing (NGS) has revolutionized high-throughput RNA analysis, it accounts for the largest share of the market. Transcriptomic research has experienced a revolution due to NGS technologies like RNA sequencing (RNA-Seq), which allow for the simultaneous and thorough investigation of accomplished transcriptomes. Furthermore, the ability to rapidly and accurately sequence millions of RNA molecules in parallel has improved researchers' ability to interpret intricate patterns of gene expression, discover new transcripts, and provide insight into alternative splicing events.

The drug discovery segment is expected to have the highest CAGR during the forecast period

Because of the advancements in pharmaceutical research and development, the drug discovery segment is predicted to see profitable expansion. Through the discovery of complex molecular pathways underlying diseases, transcriptomics offers a thorough understanding of gene expression patterns. This information helps identify and validate targets in drug discovery by enabling researchers to identify genes and pathways linked to particular illnesses. Moreover, drug reactions, biomarker discovery, and safety evaluation are made easier by transcriptomic analysis, especially when using technologies such as RNA sequencing (RNA-Seq).

Region with largest share:

Because of the confluence of elements supporting greater investment, advances in technology, and scientific research, the Asia-Pacific area accounted for the largest proportion. Transcriptomic technologies are becoming more and more in demand as a result of the increased emphasis on genomics and precision medicine in nations like China, India, Japan, and South Korea. Additionally, the market is also expanding due to the availability of highly qualified researchers and rising awareness of the potential uses of transcriptomics in a variety of industries, such as environmental science, agriculture, and healthcare.

Region with highest CAGR:

Because of the growing investments in precision medicine, genomics, and joint research projects, the European region is predicted to have profitable growth. The adoption of advanced transcriptomic techniques and technical innovation have been facilitated by substantial support from academic institutions, research organizations, and government authorities. Moreover, transcriptomics is being actively used in drug discovery and development by the European biotechnology and pharmaceutical industries, which is fueling the market's growth in the region.

Key players in the market

Some of the key players in Transcriptomics market include 10X Genomics, Agilent Technologies Inc., BGI Genomics, Bio-Rad Laboratories, Dovetail Genomics, F-Hoffmann La-Roche, Fluidigm Corporation, GE Healthcare Dharmacon Inc, General Electric Company, Illuminia Inc., Merck & Co. Inc, Natera Inc, Pacific Biosciences of California Inc., PerkinElmer Inc., Promega Corporation, QiagenInc Takara Bio Inc. and Thermofisher Scientific.

Key Developments:

In May 2022, BioSkryb Genomics launched the Early Access Program (EAP) for ResolveOME. This unified, single-cell workflow amplifies the complete genome and full-length mRNA transcripts of the entire transcriptome from the same cell.

In January 2022, Parse Biosciences, a provider of single-cell sequencing solutions for researchers partnered with Research Instruments Pte Ltd to provide Parse’s Evercode Whole Transcriptome Kits (WTKs), Cell Fixation Kits, and Nuclei Fixation Kits in Singapore and Southeast Asia.

Components Covered:
• Instruments
• Services
• Consumables
• Software
• Reagents
• Other Components

Technologies Covered:
• Next-Generation Sequencing (NGS)
• Microarrays
• Real-time Quantitative Polymerase Chain Reaction (Q-PCR)
• Sequencing Technology
• Polymerase Chain Reaction (PCR)
• Sanger
• Other Technologies

Applications Covered:
• Clinical Diagnostics
• Drug Discovery
• Diagnostics and Disease Profiling
• Toxic genomics
• Other Applications

End Users Covered:
• Pharmaceutical and Biotechnology Companies
• Government Institutes and Academic Centers
• Contract Research Organizations
• Hospitals
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements